AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
Seeking Alpha3h
Acadia Pharmaceuticals: Proving The Naysayers Wrong
The first is Nuplazid, which was approved in 2016 and remains the only approved treatment for hallucinations and delusions ...
Make this one lifestyle change to lower your Parkinson’s disease risk
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.
The Pharma Letter19h
Growing emphasis on disease-modifying therapies in Parkinson’s
The Parkinson’s disease (PD) therapeutic landscape is heavily ... With current treatments largely focused on motor symptoms, ...